PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ — The following statement is being issued by Kroll Settlement Administration LLC regarding Patel v. Edwards Lifesciences Corp., Case No. 8:24-cv-02221-AH-KES, pending in the United States District Court for the Central District of California.

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
SOUTHERN DIVISION

SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND
PROPOSED SETTLEMENT; (II) SETTLEMENT HEARING; AND
(III) MOTION FOR ATTORNEYS’ FEES AND LITIGATION EXPENSES

TO: All persons or entities who purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards”) common stock during the period from February 6, 2024 through July 24, 2024, inclusive (the “Class Period”), and were damaged thereby (“Settlement Class”)¹:

PLEASE READ THIS NOTICE CAREFULLY; YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Central District of California (“Court”), that the above-captioned securities class action (the “Action”) is pending in the Court.

YOU ARE ALSO NOTIFIED that Lead Plaintiffs City of Fort Lauderdale Police & Firefighters’ Retirement System and Louisiana Sheriffs’ Pension & Relief Fund (together, “Lead Plaintiffs”), on behalf of themselves and the Settlement Class, and Defendants Edwards and Bernard J. Zovighian (together, “Defendants”) have reached a proposed settlement of the Action on behalf of the Settlement Class for $39,000,000 in cash (the “Settlement”). If approved by the Court, the Settlement will resolve all claims in the Action.

In the Action, Lead Plaintiffs assert federal civil securities law claims against Edwards and its Chief Executive Officer, Bernard J. Zovighian, arising from purportedly materially false and misleading statements to investors during the Class Period concerning the growth prospects of Edwards’ core product, its transcatheter aortic valve replacement (“TAVR”) platform. Lead Plaintiffs allege that Defendants’ alleged misstatements violated Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), and that Mr. Zovighian controlled Edwards when the misstatements were made, in violation of Section 20(a) of the Exchange Act. Defendants expressly deny that Lead Plaintiffs have asserted any valid claims as to either of them, and expressly deny any and all allegations of fault, liability, wrongdoing, or damages whatsoever in connection with the Action. Issues and defenses at issue in the Action included, among others, (i) whether Defendants made materially false statements or omissions; (ii) whether Defendants made the statements with the required state of mind; (iii) whether the alleged misstatements caused class members’ losses; and (iv) the amount of damages, if any.²

A hearing (“Settlement Hearing”) will be held on December 16, 2026, at 1:30 p.m. Pacific Time, before the Honorable Anne Hwang, United States District Court Judge for the Central District of California, in Courtroom 9C, 9th Floor of the Felicitas and Gonzalo Mendez United States Courthouse, 350 W 1st Street, Los Angeles, CA 90012. At the Settlement Hearing, the Court will consider: (i) whether, for purposes of the Settlement only, the Action should be certified as a class action on behalf of the Settlement Class, Lead Plaintiffs should be appointed as Class Representatives for the Settlement Class, and Lead Counsel should be appointed as Class Counsel for the Settlement Class; (ii) whether the proposed Settlement on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate to the Settlement Class, and should be finally approved by the Court; (iii) whether a Judgment substantially in the form attached as Exhibit B to the Stipulation should be entered dismissing the Action with prejudice against Defendants and granting the releases specified and described in the Stipulation (and in the Notice); (iv) whether the proposed Plan of Allocation for the proceeds of the Settlement is fair and reasonable and should be approved; (v) whether the motion by Lead Counsel for attorneys’ fees and Litigation Expenses should be approved; and (vi) any other matters that may properly be brought before the Court in connection with the Settlement. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the website for the Settlement, www.EdwardsLifesciencesSecuritiesLitigation.com.

If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement proceeds. This notice provides only a summary of the information contained in the full Notice. You may obtain a copy of the Notice and the Claim Form on the Settlement website, www.EdwardsLifesciencesSecuritiesLitigation.com; by contacting the Claims Administrator at:  Edwards Lifesciences Securities Litigation, c/o Kroll Settlement Administration, PO Box 5014, New York, NY 10150-5014; by calling toll free 1-833-930-0555; or by emailing info@EdwardsLifesciencesSecuritiesLitigation.com.

To be eligible to receive a payment from the Settlement, you must be a member of the Settlement Class and submit a Claim Form postmarked (if mailed), or online, no later than December 2, 2026, in accordance with the instructions set forth in the Claim Form. If you are a Settlement Class Member and do not submit a proper Claim Form, you will not be eligible to share in the Settlement proceeds, but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

If you are a member of the Settlement Class and wish to exclude yourself from the Settlement Class, you must submit a request for exclusion such that it is received no later than December 2, 2026, in accordance with the instructions set forth in the Notice. If you properly exclude yourself from the Settlement Class, you will not be bound by any judgments or orders entered by the Court in the Action and you will not receive any benefits from the Settlement.

Any objections to the proposed Settlement, the proposed Plan of Allocation, and/or Lead Counsel’s motion for attorneys’ fees and expenses must be filed with the Court and delivered to Lead Counsel and Defendants’ Counsel such that they are received no later than December 2, 2026, in accordance with the instructions set forth in the Notice.

PLEASE DO NOT CONTACT THE COURT, THE CLERK’S OFFICE, DEFENDANTS, OR DEFENDANTS’ COUNSEL REGARDING THIS NOTICE. All questions about this notice, the Settlement, or your eligibility to participate in the Settlement should be directed to the Claims Administrator or Lead Counsel.

Requests for the Notice and Claim Form should be made to the Claims Administrator:

Edwards Lifesciences Securities Litigation
c/o Kroll Settlement Administration
PO Box 5014
New York, NY 10150-5014

1-833-930-0555
info@EdwardsLifesciencesSecuritiesLitigation.com
www.EdwardsLifesciencesSecuritiesLitigation.com

All other inquiries should be made to Lead Counsel:

Bernstein Litowitz Berger & Grossmann LLP
Jeremy P. Robinson
1251 Avenue of the Americas
New York, NY 10020

1-800-380-8496
settlements@blbglaw.com

BY ORDER OF THE COURT
United States District Court
Central District of California

¹ Certain persons and entities are excluded from the Settlement Class by definition, as set forth in the full Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys’ Fees and Litigation Expenses (the “Notice”), available at www.EdwardsLifesciencesSecuritiesLitigation.com.

² Capitalized terms not otherwise defined herein shall have the same meaning as in the Stipulation and Agreement of Settlement dated July 1, 2026 (“Stipulation”). The Stipulation can be viewed at www.EdwardsLifesciencesSecuritiesLitigation.com.

View original content:https://www.prnewswire.com/news-releases/notice-of-pendency-and-proposed-settlement-of-class-action-announced-in-edwards-lifesciences-securities-litigation-302870467.html

SOURCE Kroll Settlement Administration LLC